Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07468500) titled 'Real World Adherence of PCSK9 Targeted Therapy' on March 5.
Study Type: Observational
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Dyslipidemia
Hypercholesterolemia
Recruitment Status: Not recruiting
Date of First Enrollment: March 15, 2026
Target Sample Size: 3600
To know more, visit https://clinicaltrials.gov/study/NCT07468500
Published by HT Digital Content Services with permission from Health Daily Digest....